Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

June 16, 2020

Study Completion Date

November 24, 2020

Conditions
Biliary Tract Cancer
Interventions
DRUG

Varlitinib

Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)

DRUG

Cisplatin

On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine

DRUG

Gemcitabine

On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.

Trial Locations (3)

Unknown

Singapore

Seoul

Taipei

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER